This database contains 59 studies, archived under the term: "nootropic agents"
Click here to filter this large number of results.
Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy
Modrego, P. J.,
Fayed, N.,
Errea, J. M.,
Rios, C.,
Pina, M. A.,
Sarasa, M.
Background and Purpose: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil.; Methods: In this comparative rater-blinded parallel group randomized trial we recruited a […]
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Martorana, Alessandro,
Di Lorenzo, Francesco,
Esposito, Zaira,
Lo Giudice, Temistocle,
Bernardi, Giorgio,
Caltagirone, Carlo,
Koch, Giacomo
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Cheol Kwon,,
Eung Gyu Kim,,
Jae Woo Kim,,
Oh Dae Kwon,,
Bong Goo Yoo,,
Hyon Ah Yi,,
Nack Cheon Choi,,
Seon Young Ahn,,
Byung Hwa Lee,,
Myong Jin Kang,,
Dae Seob Choi,
Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or […]
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]
A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease
Grove, Richard A.,
Harrington, Conn M.,
Mahler, Andreas,
Beresford, Isabel,
Maruff, Paul,
Lowy, Martin T.,
Nicholls, Andrew P.,
Boardley, Rebecca L.,
Berges, Alienor C.,
Nathan, Pradeep J.,
Horrigan, Joseph P.
Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment for subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: In this 16-week, double-blind, randomized, parallel group study, 196 currently […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]